SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on October 19, 2015. The registrant is headquartered in Sydney, New South Wales, Australia. The filing serves to report a change of address for the company's principal executive office.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics. This report is administrative in nature and does not contain financial statements.
Material Changes
The material change disclosed in this filing is the update of the company's principal executive office address to Level 7, 151 Macquarie Street, Sydney, 2000, New South Wales, Australia. No financial or operational changes were reported.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the address change.
Key Facts for Investor Verification
- The company's principal executive office is now located at Level 7, 151 Macquarie Street, Sydney, 2000, New South Wales, Australia.
- The filing was signed by Marc Voigt, Chief Executive Officer, on October 19, 2015.
- No financial performance data or strategic updates are included in this specific filing.